The power of the technology was demonstrated with the rapid development of COVID-19 vaccines and it has the potential to treat previously intractable diseases.
TORONTO (PRWEB)
February 08, 2022
The advent of mRNA-based vaccines and therapeutics has resulted from decades of research into the biology of mRNA and the development of nanoparticle technology. The power of the technology was demonstrated with the rapid development of COVID-19 vaccines and it has the potential to treat previously intractable diseases.
In this presentation, our featured speaker will discuss the considerations for the development, manufacturing, and characterization of mRNA molecules and how Curia is using its combined experience in biologics and chemistry to create an end-to-end solution for this therapeutic modality.
Register for this webinar to learn about:
-
History of mRNA Technology - mRNA Therapeutic Platforms & Applications
- Development and Drug Substance Manufacturing
- Key Ingredients and Supply Chain
- Analytics
- Future Prospects
Join Curia’s Vice President, Global Head of R&D Technology, Norman Garceau, PhD for the live webinar on Wednesday, February 23, 2022 at 2pm EST.
For more information, or to register for this event, visit Considerations for the Development and Manufacturing of mRNA-based Therapeutics.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Share article on social media or email: